Geusens, Piet http://orcid.org/0000-0002-7547-9146
Kendler, David L.
Fahrleitner-Pammer, Astrid http://orcid.org/0000-0002-5590-0888
López-Romero, Pedro http://orcid.org/0000-0001-9066-1109
Marin, Fernando http://orcid.org/0000-0003-2899-9840
Clinical trials referenced in this document:
Documents that mention this clinical trial
Distribution of Prevalent and Incident Vertebral Fractures and Their Association with Bone Mineral Density in Postmenopausal Women in the Teriparatide Versus Risedronate VERO Clinical Trial
https://doi.org/10.1007/s00223-020-00683-6
Funding for this research was provided by:
Eli Lilly and Company
Article History
Received: 26 November 2019
Accepted: 17 January 2020
First Online: 10 March 2020
Compliance with Ethical Standards
:
: Dr. Geusens received consultant and/or speaker fees from Lilly, and research support from Pfizer, Abbott, Lilly, Amgen, MSD, Roche, UCB, BMS, Mylan and Novartis. Dr. Kendler received honoraria, research grants, and/or consultant fees from Amgen, Lilly, Radius, Pfizer, and UCB. Dr. Fahrleitner-Pammer received speaker fees from Amgen, Alexion, BMS, Lilly, Fresenius, Sandoz, Shire and UCB. Drs. Marin and López-Romero are employees and shareholders of Lilly.
: This article does not contain any studies with human or animal subjects performed by any of the authors.